Related references
Note: Only part of the references are listed.Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Germline variation at 8q24 and prostate cancer risk in men of European ancestry (vol 9, 4616, 2018)
Marco Matejcic et al.
NATURE COMMUNICATIONS (2019)
Promoter of IncRNA Gene PVT1 Is a Tumor-Suppressor DNA Boundary Element
Seung Woo Cho et al.
CELL (2018)
Long noncoding RNA PVT1 promotes EMT via mediating microRNA-186 targeting of Twist1 in prostate cancer
Zhongwen Chang et al.
GENE (2018)
Long non-coding RNA PVT1 predicts poor prognosis and induces radioresistance by regulating DNA repair and cell apoptosis in nasopharyngeal carcinoma
Yi He et al.
CELL DEATH & DISEASE (2018)
Downregulation of lncRNA PVT1 expression inhibits proliferation and migration by regulating p38 expression in prostate cancer
Bo Wan et al.
ONCOLOGY LETTERS (2018)
LncRNA PVT1 promotes malignant progression in squamous cell carcinoma of the head and neck
Changyun Yu et al.
JOURNAL OF CANCER (2018)
lncRNA PVT1 identified as an independent biomarker for prognosis surveillance of solid tumors based on transcriptome data and meta-analysis
Xiaoliang Chen et al.
CANCER MANAGEMENT AND RESEARCH (2018)
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015 A Systematic Analysis for the Global Burden of Disease Study
Christina Fitzmaurice et al.
JAMA ONCOLOGY (2017)
LncRNA PVT1 predicts prognosis and regulates tumor growth in prostate cancer
Jin Yang et al.
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY (2017)
Long non-coding RNA PVT1 as a novel biomarker for diagnosis and prognosis of non-small cell lung cancer
Di Cui et al.
TUMOR BIOLOGY (2016)
PVT1 Exon 9: A Potential Biomarker of Aggressive Prostate Cancer?
Adeodat Ilboudo et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2016)
Common variants at PVT1, ATG13-AMBRA1, AHI1 and CLEC16A are associated with selective IgA deficiency
Paola G. Bronson et al.
NATURE GENETICS (2016)
LncRNA PVT1 regulates prostate cancer cell growth by inducing the methylation of miR-146a
Hong-tao Liu et al.
CANCER MEDICINE (2016)
The lncRNA PVT1 Contributes to the Cervical Cancer Phenotype and Associates with Poor Patient Prognosis
Marissa Iden et al.
PLOS ONE (2016)
Long noncoding RNA PVT1 indicates a poor prognosis of gastric cancer and promotes cell proliferation through epigenetically regulating p15 and p16
Rong Kong et al.
MOLECULAR CANCER (2015)
Long non-coding RNA PVT1 is associated with tumor progression and predicts recurrence in hepatocellular carcinoma patients
Chaofeng Ding et al.
ONCOLOGY LETTERS (2015)
The PVT1-MYC duet in cancer
Yuen-Yi Tseng et al.
MOLECULAR & CELLULAR ONCOLOGY (2015)
Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers
Y. Takahashi et al.
BRITISH JOURNAL OF CANCER (2014)
Frequent Mutation of rs13281615 and Its Association with PVT1 Expression and Cell Proliferation in Breast Cancer
Zhiqian Zhang et al.
JOURNAL OF GENETICS AND GENOMICS (2014)
Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma
Erick Riquelme et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Expression and prognostic impact of lncRNAs in acute myeloid leukemia
Ramiro Garzon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Prostate cancer risk-associated genetic markers and their potential clinical utility
Jianfeng Xu et al.
ASIAN JOURNAL OF ANDROLOGY (2013)
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
T. Karantanos et al.
ONCOGENE (2013)
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim Fizazi et al.
LANCET ONCOLOGY (2012)
Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways
Olorunseun O. Ogunwobi et al.
CLINICAL & EXPERIMENTAL METASTASIS (2011)
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann S. De Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3
M. Wunderlich et al.
LEUKEMIA (2010)
Survival following primary androgen deprivation therapy among men with localized prostate cancer
Grace L. Lu-Yao et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
The PVT-1 oncogene is a myc protein target is overexpressed in transformed cells
Letizia Carramusa et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2007)
Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer
Yinghui Guan et al.
CLINICAL CANCER RESEARCH (2007)
Share Paper
